KRAS and lung carcinoma: Collectively, these results demonstrated that concurrent expression of oncogenic KRAS and mutant TP53 in the imPAC2 cells rendered the imPAC2 cells tumor-like phenotype and upregulated numerous lung cancer-related pathways, suggesting the imPAC cells may be exploited to model lung tumorigenesis.